The FDA’s Oncologic Drugs Advisory Committee narrowly voted against the approval of Zusduri, citing the lack of a completely ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert ...